Serina Therapeutics (SER) Non-Current Assets (2017 - 2026)
Serina Therapeutics (SER) posted Non-Current Assets of $871000.0 for Q4 2025, down 4.91% sequentially from $916000.0 in Q3 2025, and down 16.89% YoY from $1.0 million in Q4 2024.
Serina Therapeutics (SER) Non-Current Assets (2017 - 2026) Analysis & Trends
Serina Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $871000.0 in Q4 2025.
- Quarterly Non-Current Assets fell 16.89% year-over-year to $871000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.7 million (down 45.14% YoY) and the FY2025 annual result came in at $871000.0, down 16.89% from the prior year.
- Non-Current Assets slipped to $871000.0 in Q4 2025 per SER's latest filing, from $916000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $11.1 million in Q3 2023 and troughed at -$1.2 million in Q1 2023.
- A 5-year average of $1.4 million and a median of $951000.0 in 2021 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 1248.23% in 2023, down 240.92% in 2023.
- Over 5 years, Non-Current Assets stood at $920000.0 in 2021, then retreated by 14.35% to $788000.0 in 2022, then jumped by 71.19% to $1.3 million in 2023, then retreated by 22.31% to $1.0 million in 2024, then fell by 16.89% to $871000.0 in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $871000.0, $916000.0, and $950000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Serina Therapeutics | 46.70 Mn | 23.67 Mn | - | 784,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 784,000.00 |
| Dec 31, 2025 | 871,000.00 |
| Sep 30, 2025 | 916,000.00 |
| Jun 30, 2025 | 950,000.00 |
| Mar 31, 2025 | 977,000.00 |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 2.01 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.92 Mn |
| Dec 31, 2023 | 1.35 Mn |
| Sep 30, 2023 | 11.07 Mn |
| Jun 30, 2023 | -853,000.00 |
| Mar 31, 2023 | -1.25 Mn |
| Dec 31, 2022 | 788,000.00 |
| Sep 30, 2022 | 821,000.00 |
| Jun 30, 2022 | 854,000.00 |
| Mar 31, 2022 | 887,000.00 |
| Dec 31, 2021 | 920,000.00 |
| Sep 30, 2021 | 952,000.00 |
| Jun 30, 2021 | 985,000.00 |